PRECIGEN, INC. Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests
PRECIGEN, INC. (PGEN) reported Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests of $913.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2020-03-02.
Discontinued › Shareholders' Equity › Noncontrolling Interest Items
us-gaap:MinorityInterestDecreaseFromRedemptions · last filed 2020-03-02
- PRECIGEN, INC. noncontrolling interest, decrease from redemptions or purchase of interests for the quarter ending 2017-12-31 was $0.00.
- PRECIGEN, INC. noncontrolling interest, decrease from redemptions or purchase of interests for the quarter ending 2017-09-30 was $0.00.
- PRECIGEN, INC. noncontrolling interest, decrease from redemptions or purchase of interests for the quarter ending 2017-06-30 was $0.00.
- PRECIGEN, INC. noncontrolling interest, decrease from redemptions or purchase of interests for the quarter ending 2017-03-31 was $913.00K.
- PRECIGEN, INC. noncontrolling interest, decrease from redemptions or purchase of interests for fiscal 2017 was $913.00K.
- PRECIGEN, INC. noncontrolling interest, decrease from redemptions or purchase of interests for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- PRECIGEN, INC. noncontrolling interest, decrease from redemptions or purchase of interests for fiscal 2015 was $1.57M.
| Period end | Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 3 month | Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 6 month | Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 9 month | Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $913.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $913.00K 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $913.00K 10-Q · filed 2017-08-09 | ||
| 2017-03-31 | $913.00K 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $0.00 derived: sum of 2 quarters · filed 2018-03-01 | $0.00 derived: sum of 3 quarters · filed 2018-03-01 | $1.57M 10-K · filed 2018-03-01 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $0.00 derived: sum of 2 quarters · filed 2015-11-09 | $1.57M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $1.57M 10-Q · filed 2015-08-10 | ||
| 2015-03-31 | $1.57M 10-Q · filed 2015-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |